Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

07.11.2023 - Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week ...

Related Keywords

Texas ,United States ,Remi Barbier ,Eric Schoen ,Cassava Sciences ,Cassava Sciences Inc ,Cassava Science ,Safety Monitoring Board ,Third Quarter ,More Information Contact ,Chief Financial ,Note Regarding Forward Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Financial Tables Follow ,